VYNE Therapeutics (VYNE) Stock Highlights

2.82 | +3.3%

2024-11-21 06:13:59

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ and ZILXI.

Statistics

Range Today

2.71 2.89

Volume Today 57.7K

Range 1 Year

1.57 4.24

Volume 1 Year 20.42M

Range 3 Year

1.57 31.5

Volume 3 Year 108.66M

Range 10 Year

1.57 2869.92

Volume 10 Year 134.12M

Highlights

Market Capitalization 46.61M (micro)

Floating Shares 10.07M

Current Price 2.82

Price To Earnings 1.83

Price To Revenue -65.41

Price To Book 0.5

Earnings Per Share 1.72

Payout Ratio 0%

Performance

Latest +3.3%

1 Month +28.77%

3 Months +54.1%

6 Months +0.71%

1 Year -29.5%

3 Years -86.01%

5 Years -99.06%

10 Years -99.81%

Benchmarks

Market Capitalization

311 / 368

Gross Profits

135 / 278

Total Revenue

258 / 300

Total Rank

65 / 368

Free Cashflow

89 / 352

Performance 5 years

355 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.